# A Study of PD5K3 in Healthy Adult Volunteers

> **NCT06527781** · PHASE1 · COMPLETED · sponsor: **Chongqing Peg-Bio Biopharm Co., Ltd.** · enrollment: 28 (actual)

## Conditions studied

- Lymphoblastic Leukemia, Acute
- Lymphoblastic Lymphoma

## Interventions

- **DRUG:** PD5K3
- **DRUG:** Placebo
- **DRUG:** Pegaspargase

## Key facts

- **NCT ID:** NCT06527781
- **Lead sponsor:** Chongqing Peg-Bio Biopharm Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-27
- **Primary completion:** 2024-05-20
- **Final completion:** 2024-05-20
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2024-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06527781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06527781, "A Study of PD5K3 in Healthy Adult Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06527781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*